Evaxion Biotech A/S
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $27.6M
- Price
- $3.31
- % Change (Daily % change from the live per-ticker quote feed.)
- +0.91%
- Volume
- 540.8K
About
Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases. The company's oncology portfolio features several promising candidates: EVX-01, a leading cancer immunotherapy currently in Phase IIb clinical trials for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy undergoing Phase IIa trials for adjuvant melanoma; and EVX-03, another DNA-based immunotherapy in development for a range of cancers. Beyond oncology, Evaxion is advancing three pre-clinical vaccine candidates—EVX-B1, EVX-B2, and EVX-V1—aimed at combating various bacterial and viral pathogens. Founded in 2008, Evaxion Biotech A/S is headquartered in Hørsholm, Denmark.
Quick stats
Shares outstanding8.3M
Computed float5.1M
Float / shares61.2%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001828253
Websitehttps://evaxion.ai
AI Summary
AI-generated1/26
minorneutraloperations update
Evaxion announces business update and second quarter 2026 financial results
Evaxion reported a Q2 net loss of $3.7 million, narrowing from $4.8 million in the year-ago quarter, with cash and equivalents of $14.0 million funding operations into the second half of 2027.
Pipeline progress includes upcoming three-year data for EVX-01 in melanoma at ESMO 2026, new data for EVX-04 in AML, and the expansion of its off-the-shelf pipeline with EVX-05 for glioblastoma.
The company also highlighted external validation for its AI-Immunology™ platform, winning the 2026 Prix Galien UK Award for Best digital health solution.
Red flags
- Cash position declined from $18.4 million to $14.0 million quarter-over-quarter